Explore All 508 Buyout (LBO, MBO, MBI) Apparel/Textiles Deals - Search the Database Free
M&A Deal Summary |
|
|---|---|
| Date | May 1, 1991 |
| Target | Groupe Kindy |
| Sector | Apparel/Textiles |
| Buyer(s) | Permira |
| Deal Type | Buyout (LBO, MBO, MBI) |
FILTER BY
| Category | Private Equity Firm |
|---|---|
| Founded | 1985 |
| PE ASSETS | 80.0B EUR |
| Size | Mega |
| Type | Sector Agnostic |
Permira is a mega-sized private equity firm that targets large company investments around the world. Permira invests to support acquisitions, leveraged buyouts, take-privates, turnarounds, and growth buyouts. Areas of interest include healthcare, financial services, chemicals, consumer products and services, industrial products and services, technology, media, and telecom. Permira will consider opportunities in Europe, Asia, and North America. Permira was formed in 1985 and has offices in Menlo Park, Frankfurt, Luxembourg, London, Hong Kong, Madrid, Milan, Paris, Stockholm, Tokyo, Guernsey and New York City.
| Deal Context for Buyer | # |
|---|---|
| Overall | 6 of 171 |
| Sector: Apparel/Textiles | 1 of 6 |
| Type: Buyout (LBO, MBO, MBI) | 6 of 55 |
| Country: France | 1 of 9 |
| Year: 1991 | 2 of 2 |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 1991-01-01 |
Ushers of Trowbridge
Brixham, United Kingdom Ushers of Trowbridge Ltd is a operator of Drinking Places in Liskeard. |
Buy | - |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 1992-01-01 |
Chiroscience
Brussels, Belgium Chiroscience was originally a speciality chemicals business, supplying 'chiral' intermediates to the drug industry. It was founded in 1987 as Enzymatix with initial funding from the British Sugar Corporation (part of Berisford International).The Permira Funds invested in the buyout from Berisford in March 1992. The well known UK biotech entrepreneur, Sir Christopher Evans, was Chief Scientific Officer.A further round of private funding, led by the Permira Funds in June 1993, and a public flotation in February 1994, helped finance the company's transformation into a fully-fledged drug discovery business. |
Buy | - |
